Korean J Med.  2022 Aug;97(4):229-237. 10.3904/kjm.2022.97.4.229.

Chimeric Antigen Receptor-T Cell Therapy

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Abstract

Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.

Keyword

키메릭 항원 수용체; CAR-T 세포 치료; 림프종; 다발골수종; Chimeric antigen receptor; CAR-T cell therapy; Lymphoma; Multiple myeloma
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr